Viva Star Biosciences Ltd. has synthesized lysophosphatidic acid receptor 1 (LPAR1; EDG2) antagonists reported to be useful for the treatment of fibrosis, chronic kidney disease, diabetic nephropathy, ...
Horizon Therapeutics plc HZNP announced that it has enrolled the first patient in a pivotal phase IIb study evaluating its lysophosphatidic acid receptor 1 (LPAR1) antagonist, HZN-825, for the ...
Haisco Pharmaceutical Group Co. Ltd. has described lysophosphatidic acid receptor 1 (LPAR1; EDG2) antagonists reported to be useful for the treatment of idiopathic pulmonary fibrosis, systemic ...
-- Gained Rights to Product Candidate, CZN001 (renamed HZN-825), a Potential Treatment for Diffuse Cutaneous Systemic Sclerosis; a Rare Rheumatic Disease with No FDA-Approved Treatment -- -- ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results